Holen Sie sich die Stockscreener-App
5.79
7.42%
0.40
Vorhandelsmarkt:
5.84
0.05
+0.86%
Schlusskurs vom Vortag:
$5.39
Offen:
$5.36
24-Stunden-Volumen:
1.89M
Relative Volume:
1.39
Marktkapitalisierung:
$282.55M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-54.19M
KGV:
-2.2442
EPS:
-2.58
Netto-Cashflow:
$-37.34M
1W Leistung:
+5.46%
1M Leistung:
+17.68%
6M Leistung:
-1.19%
1J Leistung:
+22.93%
1-Tages-Spanne:
$5.31
$5.9088
1-Wochen-Bereich:
$5.25
$6.16
52-Wochen-Spanne:
$3.9328
$7.3236
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Firmenname
Abeona Therapeutics Inc
Sektor
Branche
Telefon
646-813-4701
Adresse
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Vergleichen Sie ABEO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
5.79 | 267.91M | 0 | -54.19M | -37.34M | -2.58 |
|
ONC
Beigene Ltd Adr
|
225.77 | 25.49B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.38 | 110.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.32 | 38.69M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
584.99 | 59.13B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
69.53 | 5.64B | 0 | -153.72M | -103.81M | -2.00 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-05 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-30 | Eingeleitet | Stifel | Buy |
| 2020-11-11 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-09-18 | Eingeleitet | B. Riley FBR | Buy |
| 2020-02-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-12-10 | Fortgesetzt | Cantor Fitzgerald | Neutral |
| 2019-08-15 | Herabstufung | Maxim Group | Buy → Hold |
| 2019-08-12 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-07-26 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-06-27 | Eingeleitet | Mizuho | Buy |
| 2018-10-12 | Eingeleitet | Mizuho | Buy |
| 2018-06-05 | Eingeleitet | Seaport Global Securities | Buy |
| 2017-11-08 | Eingeleitet | SunTrust | Buy |
| 2017-10-16 | Bestätigt | H.C. Wainwright | Buy |
| 2017-10-11 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-10-10 | Eingeleitet | Citigroup | Buy |
| 2017-10-05 | Bestätigt | Maxim Group | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-07-18 | Bestätigt | Maxim Group | Buy |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2017-01-06 | Eingeleitet | Jefferies | Buy |
| 2016-09-29 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Abeona Therapeutics Inc Aktie (ABEO) Neueste Nachrichten
Abeona Therapeutics (ABEO) Transitions to Commercial Stage with ZEVASKYN Launch - GuruFocus
Abeona Therapeutics: Q1 Earnings Snapshot - Midland Daily News
Abeona Therapeutics (ABEO) Target Price Raised Following FDA Approval and Strategic Sale | ABEO Stock News - GuruFocus
Earnings call transcript: Abeona Therapeutics beats EPS forecast in Q1 2025 - Investing.com
Abeona Therapeutics (ABEO) Exceeds EPS Estimates, Bolstered by S - GuruFocus
ABEO Shows Decrease in Cash Reserves Before PRV Sale Completion - GuruFocus
Abeona Therapeutics (ABEO) Launches ZEVASKYN, A Milestone in Gen - GuruFocus
Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates | ABEO Stock News - GuruFocus
ABEO Shows Decrease in Cash Reserves Before PRV Sale Completion | ABEO Stock News - GuruFocus
Abeona Therapeutics (ABEO) Launches ZEVASKYN, A Milestone in Gene Therapy | ABEO Stock News - GuruFocus
ABEONA THERAPEUTICS INC. SEC 10-Q Report - TradingView
Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates - GlobeNewswire
Breakthrough: First-Ever Gene Therapy for Rare Skin Disease Launches as Abeona Secures $155M Deal - Stock Titan
US FDA Orphan Drug Rare Disease Market Clinical Trials Drug Sales Insight 2030 - GlobeNewswire Inc.
UPDATE -- Abeona Therapeutics® and Lurie Children's Open First C - GuruFocus
Abeona Therapeutics® and Lurie Children's Open First Center for - GuruFocus
Abeona Therapeutics (ABEO) Initiates Gene Therapy Rollout for Sk - GuruFocus
Best Momentum Stocks to Buy for May 8th - The Globe and Mail
UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene ... - Eagle-Tribune
UPDATE -- Abeona Therapeutics® and Lurie Children's Open - GlobeNewswire
Breakthrough Gene Therapy ZEVASKYN Launches: First Treatment Center Opens for Rare Skin Disease RDEB - Stock Titan
Abeona Therapeutics® and Lurie Children's Open First Center - GlobeNewswire
Abeona Therapeutics And Lurie Children's Open First Center For Zevaskyntm Gene Therapy - marketscreener.com
First-Ever Gene Therapy Treatment Center Opens for Devastating Skin Disease RDEBWhat Patients Need to Know - Stock Titan
Abeona Therapeutics: Strong Buy Rating Backed by Financial Stability and Strategic Growth Initiatives - TipRanks
Abeona secures cash runway with $155m priority review voucher sale - Yahoo
Abeona sells FDA voucher for $155 million, eyes profitability By Investing.com - Investing.com Canada
Cleveland company enters $155M agreement to sell FDA voucher - Crain's Cleveland Business
Abeona Therapeutics to Sell Zevaskyn Priority Review Voucher for $155 Million; Shares Rise - marketscreener.com
Abeona sells speedy drug review voucher for $155M - BioPharma Dive
Abeona sells FDA voucher for $155 million, eyes profitability - Investing.com Australia
Abeona Therapeutics (ABEO) Plans to Sell Priority Review Voucher for $155 Million | ABEO Stock News - GuruFocus
Abeona Therapeutics Sells Priority Review Voucher for $155M - TipRanks
Abeona Therapeutics® Enters into Agreement to Sell Priority Revi - GuruFocus
Abeona Therapeutics Enters Into Agreement To Sell Priority Review Voucher - marketscreener.com
Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million - GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ABEO Stock News - GuruFocus
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
StockWatch: Second Time’s the Charm for Abeona’s Gene Therapy - Genetic Engineering and Biotechnology News
Abeona Therapeutics’ Gene Therapy Gets FDA Nod For Treating Rare Genetic Skin Disease - MSN
Abeona Therapeutics (ABEO) Gains FDA Approval for Gene Therapy | ABEO Stock News - GuruFocus
Institutional investors control 44% of Abeona Therapeutics Inc. (NASDAQ:ABEO) and were rewarded last week after stock increased 22% - simplywall.st
FDA approves Abeona’s $3.1m cell therapy for rare skin disease - MSN
ABEO: Zevaskyn Approved by FDA Raising Valuation to 11 - Smartkarma
Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease - Benzinga
Abeona Therapeutics (ABEO) Sees Price Target Boost Amid FDA Appr - GuruFocus
Abeona Stock Surges to 52-Week High: What's Behind The Move? - Benzinga
Abeona’s ZEVASKYN Gets FDA Nod for Rare Skin Disease - Contract Pharma
FDA approves Abeona’s Zevaskyn - The Pharma Letter
Abeona prices rare cell disorder gene therapy at $3.1m - Pharmaphorum
Historic achievement: FDA approval of Abeona Therapeutics' ZEVASKYN accelerates momentum and expands treatment options for the EB community. - Olean Times Herald
Finanzdaten der Abeona Therapeutics Inc-Aktie (ABEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.17%
0.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):